Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In … – Markets Insider
|
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In …
Markets Insider “Not all patients respond to immunotherapies,” said Dr. Heinrich Roder. “The pre-treatment circulating proteome contains information that can predict durable benefit from immunotherapies. Our test development platform, an established methodology, can … |
